Tutorial in biostatistics: Sample sizes for clinical trials with Normal data

Statistics in Medicine

Volumn 23, Issue 12, 2004, Pages 1921-1986

  Julious, Steven A ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Baselines; Bioequivalence; Cross over trials; Equivalence trials; Non inferiority trials; Parallel group trials; Power; Precision; Sample size; Superiority trials; Type I error; Type II error

Indexed keywords

DRUG;

ACCURACY; ANALYTICAL ERROR; AREA UNDER THE CURVE; BIOSTATISTICS; CALCULATION; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG ABSORPTION; FOOD DRUG INTERACTION; HUMAN; HYPOTHESIS; PARALLEL DESIGN; REVIEW; SAMPLE SIZE; BIOMETRY; CONTROLLED CLINICAL TRIAL; METHODOLOGY; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL;

BIOMETRY; CROSS-OVER STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE; THERAPEUTIC EQUIVALENCY;

EID: 4344584922     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1783     Document Type: Review

References (71)

1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. British Medical Journal 1948; 2:769-782.
2. Julious SA, Zariffa N. The ABC of pharmaceutical trial design: some basic principles. The Journal of Pharmaceutical Statistic 2002; 1:45-53.
3. ICH E9. Statistical principals for clinical trials. September 1998. http://www.fda.gov/cder/guidance/ICH_E9fnl.PDF [last accessed 23 October 2003].
4. Altman DG, Bland JM. Treatment allocation in controlled trials: why randomize? British Medical Journal 1999; 318:1209.
5. Day S. Blinding or masking. In Encyclopedia of Biostatistics, vol. 1, Armitage P, Colton T (eds). John Wiley and Sons: Chichester, 1998; 410-417.
6. Altman DG. Statistics and ethics in medical research III - how large a sample? British Medical Journal 1980; 281:1336-1138.
7. ICH E3. Structure and content of clinical study reports. July 1996. http://www.fda.gov/cder/guidance/iche3.pdf [last accessed 23 October 2003].
8. Hintz JL. PASS 2000 User's Guide. Kaysville, 2000.
9. Elashoff JD. nQuery advisor version 4 user's guide. Los Angeles, 2000.
10. Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary and ordinal outcomes in paired comparisons: practical hints. Journal of Biopharmaceutical Statistics 1999; 9(2):241-251.
11. Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. British Medical Journal 1995; 311:1145-1148.
12. Donner A. Approaches to sample size estimation in the design of clinical trials - a review. Statistics in Medicine 1983; 3:199 214.
13. Machin D, Campbell MJ, Fayers P, Pinol A. Statistical Tables for the Design of Clinical Studies (2nd edn). Blackwell Scientific Publications: Oxford, 1997.
14. Koch GG, Gansky SA. Statistical considerations for multiplicity in confirmatory trials. Drug Information Journal 1996; 30:523-534.
15. CPMP. Points to consider on multiplicity issues in clinical trials. (CPMP/EWP/908/99) 19 September 2002 http://www.cmea.cu.int/pdfs/human/ewp/090899cn.pdf (last accessed 21 October 2003).
16. Gould AL. Interim analyses for monitoring clinical trials that do not materially effecct the type I error rate. Statistics in Medicine 1992; 11:55-66.
17. Gould AL. Planning and revising the sample size for a trial. Statistics in Medicine 1995; 14:1039-1051.
18. Zucker DM, Denne J. Sample size re-determination for repeated measures studies. Biometri 2002; 48(3): 548-559.
19. Zucker DM, Wittes JT, Schabenberger O, Brittain E. Internal pilot studies II. Comparison of various procedures. Statistics in Medicine 1999; 18:3493-3509.
20. Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed data with unknown variance. Communications in Statistics Theory and Methods 1992; 21:2833-2853.
21. Gould AL, Shih WJ. Modifying the design of ongoing trials without unblinding. Statistics in Medicine 1998; 17:89-100.
22. Birkett MA, Day SJ. Internal Pilot studies for estimating sample size. Statistics in Medicine 1994; 13: 2455-2403.
23. Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Statistics in Medicine 2000; 19:901-911.
24. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficacy of clinical trials. Statistics in Medicine 1990; 9:65-72.
25. Neyman J, Pearson ES. On the use and interpretation of test criteria. Biometrika 1928: 20(A):175-194.
26. Neyman J, Pearson ES. On the problem of the most efficient tests of statistical hypotheses. Philosophical Transitions Royal Society (London) 1933; 23:289-237.
27. Neyman J, Pearson ES. The testing of statistical hypotheses in relation to the probabilities a priori. Proceeds of the Cambridge Philosophical Society 1933; 29:492-510.
28. Neyman J, Pearson ES. Contributions to the theory of testing hypotheses. Journal Statistical Research Memoirs (University of London) 1936; 1:1-37.
29. Neyman J, Pearson ES. Sufficient statistics and uniformly most powerful test of statistical hypothesis. Journal Statistical Research Memoirs (University of London) 1936; 1:13-137.
30. Neyman J, Pearson ES. Contributions to the theory of testing statistical hypotheses. Journal Statistical Research Memoirs (University of London) 1938; 2:25-57.
31. Fayers P, Machin D. Sample size: how many patients are necessary? British Journal of Cancer 1995; 72:1-9.
32. Armitage P, Berry G. Statistical Methods in Medical Research (3rd edn). Blackwell Science: Oxford.
33. Schouten HJA. Sample size formula with a continuous outcome for unequal group sizes and unequal variances. Statistics in Medicine 1999; 18:87-91.
34. Singer J. A simple procedure to compute sample size needed to compared two independent groups when the population variances are unknown. Statistics in Medicine 2001; 20:1995.
35. Brush GG. How to choose the proper sample size, vol. 12, The ASQC Basic References in Quality Control, Statistical Techniques, American Society for Quality Control: Milwaukee, WI, 1988.
36. Senn S. Cross-over Trials in Clinical Research. John Wiley and Sons: Chichester, 1993.
37. Chow SC, Shao J, Wang H. A note on sample size calculations for mean comparisons based on noncentral t-statistics. Journal of Pharmaceutical Statistics 2002; 12:441-456.
38. Guenther WC. Sample size formulas for normal theory t-tests. The American Statistician 1981; 35:243-244.
39. Berger RL, Hsu, JC. Bioequivalence trials, intersection-union tests and equivalence confidence sets. Statistical Science 1996; 11:283-319.
40. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. British Medical Journal 1996; 313:36-39.
41. ICH E10 Choice of control group in clinical trials, 2000. May 2001 http://www.fda.gov/cder/guidance/4155fnl.pdf (last accessed 10 November 2003).
42. CPMP. Points to consider on switching between superiority and non-inferiority. (CPMP/EWP/482/99) 17 July 2000. http://www.emea.eu.int/pdfs/human/ewp/048299en.pdf (last accessed 21 October 2003).
43. CPMP. Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on biostatistical methodological issues arising from recent CPMP discussions on licensing applications: choice of delta. (CPMP/EWP/2158/99) 23 September 1999. http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf (last accessed 21 October 2003).
44. Hung HMJ, Wang SJ, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Statistics in Medicine 2003; 22:213-225.
45. D'Agostino RB, Massaro J, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Statistics in Medicine 2003; 22:169-186.
46. Wiens BL. Choosing an equivalence limit for noninferiority and or equivalence studies. Controlled Clinical Trials 2002; 23:2-14.
47. Owen DB. A special case of a bivariate non-central t-distribution. Biometrika 1965; 52:437-446.
48. Diletti E Hauschke D, Steinijans VW. Sample size determination form bioequivalence assessment by means of confidence intervals. International Journal of Clinical Pharmacology, Therapy and Toxicology 1991; 29:1-8.
49. Morikawa T, Yoshida M. A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. Journal of Biopharmaceutical Statistics 1995; 5(3):297-306.
50. Senn S. In the blood: proposed new requirements for the registering of generic drugs. The Lancet 1998; 352:85-86.
51. FDA. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. October 2000. http://www.fda.gov/eder/guidance/3615fnl.pdf (last accessed 23 October 2003).
52. FDA. Statistical approaches to establishing bioequivalence. January 2001. http://www.fda.gov/cder/guidance/3616fnl.pdf (last accessed 23 October 2003).
53. CPMP. Note for guidance on the investigation of bioavailability and bioequivalence. (CPMP/EWP/QWP1401/98) 26 July 2001. http://www.emea.cu.int/pdf/human/ewp/140198en.pdf (last accessed 21 October 2003).
54. FDA. Guidance for industry. Food-effect bioavailability and fed bioequivalence studies. December 2000. http://www.fda.gov/cder/guidance/5194fnl.pdf (last accessed 23 October 03).
55. CPMP. Note for guidance on the investigation of drug interactions. (CPMP/EWP/560/95) 17 December 1997. http://www.emea.cu.int/pdfs/human/ewp/056095en.pdf (last accessed 21 October 2003).
56. FDA. Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labelling. November 1999. http://www.fda.gov/cder/guidance/2635fnl.pdf (last accessed 23 October 2003).
57. FDA. Guidance for industry. Pharmacokinetics in patients with impaired renal function - study design, data analysis and impact on dosing and labelling. May 1998. http://www.fda.gov/cder/guidance/1449fnl.pdf pdf (last accessed 23 October 2003).
58. FDA. Guidance for industry. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis and impact on dosing and labelling. May 2003. http://www.fda.gov/cder/guidance/3625fnl.pdf (last accessed 23 October 2003).
59. Julious SA, Debarnot CAM. Why are pharmacokinetic data summarized as arithmetic means. Journal of Biopharmaceutical Statistics 2000; 10(1):55-71.
60. Lacey JM, Keene ON, Pritchard JF, Bye A. Common non-compartmental pharmacokinetic variables: are they normally or log-normally distributed? Journal of Biopharmaceutical Statistics 1997; 7(1):171-178.
61. Liu JP. Use of the repeated cross-over designs in assessing bioequivalence. Statistics in Medicine 1995; 14:1067-1078.
62. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized trials. Statistics in Medicine 1991; 10:1665-1677.
63. Schall R, Williams RL. Towards a practical strategy for assessing individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 1996; 24:133-149.
64. Hauck WW, Anderson S. Types of bioequivalence and related statistical considerations. International Journal of Clinical Pharmacology, Therapy and Toxicology 1992; 30:181-187.
65. Day S. Clinical trial numbers and confidence intervals of pre-specified size. The Lancet 1988; 17:1427.
66. Wood J. Lambert M. Sample-size calculations for trials in health services research. Journal of Health Services and Research and Policy 1999; 4:226-229.
67. Desu MM, Raghavarao D. Sample Size Methodology. Academic Press: London, 1990.
68. CPMP. Points to consider on adjustment for baseline covariates. (CPMP/EWP/2863/99) 23 May 2003. http://www.emea.eu.int/pdfs/human/ewp/286399en.pdf (last accessed 21 October 2003).
69. Frison LJ, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implication for design. Statistics in Medicine 1992; 11:1685-1704.
70. Diggle PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford University Press: Oxford, 1996.
71. Julious SA. Repeated measures in clinical trials: analysis using means summary statistics and its implications for design. Statistics in Medicine 2000; 19:3133-3135.